Indegene Unveils NEXT Tool to Automate Medical Writing with GenAI
ECONOMY & POLICY

Indegene Unveils NEXT Tool to Automate Medical Writing with GenAI

Indegene, a digital-first, life sciences commercialization company, today announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond.

Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.

With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation—it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”

The launch of NEXT Medical Writing Automation reinforces Indegene’s commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

Indegene, a digital-first, life sciences commercialization company, today announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond.Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation—it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”The launch of NEXT Medical Writing Automation reinforces Indegene’s commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code